Fund moves
5.7%Stake · was 5.7%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Nov 13, 2026 · Notice filed Nov 13, 2026
A Dyne Therapeutics officer told the SEC about a plan to sell $93K of Dyne Therapeutics shares around Nov 13, 2026. The filing says the shares were acquired as compensation.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Johanna Friedl-naderer (Chief Commercial Officer) sold ~$3.9K of Dyne Therapeutics
Planned saleDouglas Kerr (Head of R&D and CMO) sold ~$44K of Dyne Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.